BiotechTube
BioKier

BioKier

Cambridge, United States· Est.
biokier.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $19.7M

Overview

BioKier is pioneering an oral therapeutic approach to mimic the metabolic resolution seen after gastric bypass surgery, primarily for type 2 diabetes. Its platform utilizes colon-targeted delivery of safe, nutrient-based compounds like L-glutamine to stimulate gut hormones (incretins) that regulate glucose and lipids. The company has completed multiple clinical studies, is funded by SBIR grants, and is advancing its lead programs BKR-017 and BKR-013 as medical foods and/or drugs.

Type 2 DiabetesMetabolic SyndromeObesityType 1 Diabetes

Technology Platform

Proprietary oral formulation for colon-targeted delivery of nutrient-based compounds (e.g., L-glutamine) to stimulate gut hormone (incretin) secretion for metabolic regulation.

Funding History

12
Total raised:$19.7M
Grant$436K
Series A$8M
Seed$4.5M
Grant$1.2M

Opportunities

The massive and growing global market for diabetes and obesity therapies creates a significant opportunity for a safe, oral, and physiology-based treatment.
The medical food regulatory pathway offers a potential route to early market entry and revenue generation.

Risk Factors

The company faces clinical risk in proving efficacy in larger trials and regulatory risk in navigating the medical food and 505(b)(2) pathways.
It also operates in a highly competitive market dominated by large pharma with substantial resources.

Competitive Landscape

BioKier competes in the crowded diabetes/obesity market against large pharma's injectable GLP-1s, SGLT2 inhibitors, and oral drugs. Its differentiation is an oral, nutrient-based approach mimicking surgery's hormonal effects, but it must prove superior safety/tolerability or complementary efficacy to gain share.

More companies in Small Molecule Drugs →More companies in United States →